Co-administration of finasteride and the pure anti-oestrogen ICI 182,780 act synergistically in modulating the IGF system in rat prostate

Journal of Endocrinology

Volumn 171, Issue 1, 2001, Pages 109-118

  Huynh, H ^a   Alpert, L ^a   Alaoui Jamali, M A ^a   Ng, C Y ^a   Chan, T W M ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; FINASTERIDE; FULVESTRANT; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN KINASE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATROPHY; CELL ACTIVITY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; DRUG POTENTIATION; EPITHELIUM CELL; GENE EXPRESSION; LABELING INDEX; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RAT; THICKNESS; TUMOR GROWTH;

ANIMALS; BLOTTING, NORTHERN; CELL DIVISION; DRUG SYNERGISM; ENZYME INHIBITORS; EPITHELIAL CELLS; ESTRADIOL; ESTROGEN ANTAGONISTS; FINASTERIDE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; ORGAN SIZE; PHOSPHORYLATION; PROSTATE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTOR, IGF TYPE 1; STATISTICS, NONPARAMETRIC; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0034765788     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1710109     Document Type: Article

References (66)

1. Androgen deprivation as a strategy for prostate cancer chemoprevention
2. Total androgen ablation: Canadian experience
3. High-affinity binding of oestradiol-17 beta by cytosols from testis interstitial tissue, pituitary, adrenal, liver and accessory sex glands of the male rat
4. Antiandrogens and 5-alpha reductase inhibition of the proliferation rate in PC3 and DU145 human prostatic cancer cell lines
5. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
6. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo
7. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
8. Insulin-like growth factor binding proteins and their role in controlling IGF actions
9. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells
10. The IGF axis in the prostate
11. Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia
12. Combined androgen blockade
13. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
14. Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate
15. The endocrinology and developmental biology of the prostate
16. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
17. Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853)
18. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice
19. Medical approaches in the management of prostatic disease
20. Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy
21. Finasteride in the treatment of benign prostatic hyperplasia
22. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase
23. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects
24. Chemoprevention strategies for prostate cancer: The role of 5 alpha-reductase inhibitors
25. The effect of finasteride in men with benign prostatic hyperplasia
26. Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors
27. In vivo inhibition of insulin-like growth factor-I gene expression by tamoxifen
28. Tumour suppressor activity of the gene encoding mammary-derived growth inhibitor
29. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells
30. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I), IGF-I receptor, and an increase in IGF binding protein 3
31. Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite, 1,25(OH)2D3 and its analog EB1089
32. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial
33. Insulin-like growth factors and their binding proteins: Biological actions
34. Androgen and estrogen receptors in rat ventral prostate epithelium and stroma
35. Introductory remarks: Development of chemopreventative agents for prostate cancer
36. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt
37. New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens
38. Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657
39. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor
40. A multicenter trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer
41. Identification, characterization, and regulation of a rat complementary deoxyribonucleic acid which encodes insulin-like growth factor-I
42. Pathologic changes associated with androgen deprivation therapy for prostate cancer
43. Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins
44. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4 and 5
45. Benign prostatic hyperplasia. Medical and minimally invasive treatment options
46. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells
47. Synthesis and characterization of insulin-like growth factor binding protein (IGFBP)-7 - Recombinant human MAC25 protein specifically binds IGF-I and II
48. Role of insulin-like growth factors in prostate biology
49. The developmental pattern of androgen receptor expression in rat prostate lobes is altered after neonatal exposure to estrogen
50. Estrogen receptor-beta messenger ribonucleic acid ontogeny in the prostate of normal and neonatally estrogenized rats
51. Insulin-like growth factor binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism
52. Estradiol causes a dose-dependent stimulation of prostate growth in castrated beagle dogs
53. Drug therapy - Finasteride
54. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1,-2,-3,-4,-5 and -6)
55. Inverse relation between prostate-specific antigen and insulin-like growth factor-binding protein 3 in bone metastases and serum of patients with prostate cancer
56. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia
57. Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: Clinical correlations
58. Systemic administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate
59. Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex
60. A potent specific pure antiestrogen with clinical potential
61. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells
62. The IRS-signaling system: A network of docking proteins that mediate insulin and cytokine action
63. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study
64. The IRS-signalling system during insulin and cytokine action
65. L